secwatch / observer
8-K filed April 17, 2023, 7:59 PM ET CIK 0001044378
other material confidence high sentiment negative materiality 0.85

BIOCEPT INC: auditor change — Biocept restates Q1-Q3 2022 results due to errors in stock-based compensation and revenue recognition

BIOCEPT INC

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

BIOCEPT INC reported that prior financial statements should not be relied upon.

Action
non reliance
Exact text from the filing
nd together with the March 31, 2022 Financial Statements and June 30, 2022 Financial Statements, the “Relevant Financial Statements”) as included in the previously filed Quarterly Reports on Form 10-Q for such quarters, should no longer be relied upon. While preparing the financial statements as of and for the year ended December 31, 2022, the Company discovered that there was an error in the inputs used within the black-scholes calculation for options granted in April 2019. Further, the Company discovered there was an error associated with the acceleration of stock-based compensation recorded in the March 31, 2022 Financial Statements. The Company determined that its review control over the completeness and accuracy of information used when calculating stock-based compensation expense did not operate effectively, resulting in a material error in the March 31, 2022 Financial Statements.
View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR
accession 0001193125-23-102909
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.